Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Osteoclastogenesis inhibitory factor (OCIF)/OPG]

E Tsuda, K Higashio

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |July 2, 1998
    PubMed
    Summary

    A novel factor, osteoclastogenesis inhibitory factor (OCIF), inhibits bone loss by blocking cell signaling. This discovery offers new therapeutic targets for bone diseases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Time-dependent gene expression and immunohistochemical analysis of the injured anterior cruciate ligament.

    Bone & joint research·2013
    Same author

    Knee osteoarthritis, knee joint pain and aging in relation to increasing serum hyaluronan level in the Japanese population.

    Osteoarthritis and cartilage·2010
    Same author

    Acute coronary artery dilation due to Kawasaki disease and subsequent late calcification as detected by electron beam computed tomography.

    Pediatric cardiology·2007
    Same author

    Two young adults who had acute coronary syndrome after regression of coronary aneurysms caused by Kawasaki disease in infancy.

    Pediatric cardiology·2006
    Same author

    Pregnancy and delivery in patients with coronary artery lesions caused by Kawasaki disease.

    Heart (British Cardiac Society)·2005
    Same author

    Strategy for localized stenosis caused by Kawasaki disease: midterm results of percutaneous transluminal coronary balloon angioplasty in two infants.

    Pediatric cardiology·2005

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Cell Biology

    Context:

    • Osteoclastogenesis is a critical process in bone remodeling.
    • Dysregulation of osteoclast activity leads to bone diseases like osteoporosis.
    • Identifying factors that regulate osteoclastogenesis is crucial for therapeutic development.

    Purpose:

    • To purify and characterize a novel cytokine involved in osteoclastogenesis.
    • To elucidate the molecular mechanism by which this factor inhibits osteoclast formation.
    • To assess the in vivo effects of this factor on bone metabolism.

    Summary:

    • Osteoclastogenesis inhibitory factor (OCIF), a novel heparin-binding glycoprotein, was purified from human lung fibroblasts.
    • OCIF, a soluble member of the TNF receptor superfamily, inhibits osteoclastogenesis in vitro and increases bone density in vivo.
    • Its N-terminal cysteine-rich domains are sufficient for inhibiting osteoclastogenesis by disrupting cell-to-cell signaling between osteoblasts and osteoclast progenitors.

    Impact:

    • Discovery of OCIF provides a new molecular target for treating bone diseases.
    • Understanding OCIF's mechanism offers insights into the regulation of bone remodeling.
    • Potential for developing novel therapies to increase bone mineral density and bone volume.

    Related Experiment Videos